Off-patent industry groups in the US have raised questions about why Stelara is included on the list and if CMS’ projection can match up with estimated savings that could be generated traditionally by generics and biosimilars.
“The Biosimilars Forum is greatly concerned that the Centers for Medicare & Medicaid Services is misinterpreting the Biosimilar Special Rule of the Inflation Reduction Act,” commented the Forum’s executive director Juliana Reed, in response to the recently released list of ten drugs and their negotiated prices that will come into effect on 1 January 2026.
The CMS stated that “for the first time, the law provides Medicare the ability to directly negotiate the prices of...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
